STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[6-K] Evotec SE Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Evotec SE filed a Form 6-K announcing that its management resolved on November 06, 2025 to implement a share repurchase program. The company states that the program is described in Exhibit 99.1, an announcement made pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 and Article 2(1) of Delegated Regulation (EU) No. 2016/1052.

This is an administrative disclosure indicating the company’s decision to buy back shares, with specific terms set out in the accompanying exhibit.

Positive
  • None.
Negative
  • None.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November, 2025

 

COMMISSION FILE NUMBER 001-34041

 

Evotec SE
(Translation of registrant’s name into English)

 

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

On November 06, 2025, Evotec SE (the “Company”) resolved to implement a share repurchase program as described attached hereto as Exhibit 99.1. 

 

EXHIBIT INDEX

 

Exhibit   Description of Exhibit
99.1   Announcement pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 in conjunction with Article 2(1) of Delegated Regulation (EU) No. 2016/1052

 

 

 

 

SIGNATURE

 

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Evotec SE
     
  By: /s/ Christian Wojczewski
    Name: Christian Wojczewski
    Title: Chief Executive Officer

 

Date: November 06, 2025

 

 

 

FAQ

What did Evotec SE (EVO) disclose in this Form 6-K?

Evotec SE reported it resolved to implement a share repurchase program, with details provided in Exhibit 99.1.

When did Evotec SE make the buyback decision?

The resolution to implement the share repurchase program was made on November 06, 2025.

Where can I find the terms of Evotec SE’s share repurchase program?

The program is described in Exhibit 99.1, an announcement under EU Market Abuse Regulation and its Delegated Regulation.

Which annual report format does Evotec SE use?

Evotec SE files annual reports under Form 20-F.

Who signed the report for Evotec SE?

It was signed by Christian Wojczewski, Chief Executive Officer.

What regulatory references are cited for the announcement?

Article 5(1)(a) of Regulation (EU) No. 596/2014 and Article 2(1) of Delegated Regulation (EU) No. 2016/1052.
Evotec Ag

NASDAQ:EVO

EVO Rankings

EVO Latest News

EVO Latest SEC Filings

EVO Stock Data

1.19B
355.26M
2.72%
0.21%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg